결절성 소양증 시장 보고서(2025년)

Nodular Prurigo Global Market Report 2025

US $ 4,490 ￦ 6,661,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,629,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,596,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

결절성 소양증 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 이러한 성장에 기여하는 요인은 표적 치료법의 도입, 희귀 피부 질환에 대한 연구 개발 투자 확대, 보다 강력한 환자 교육 및 옹호 활동, 보험 및 환급의 확대, 동반 진단 및 바이오마커의 개발 등입니다. 예측 기간 동안 주목할 만한 동향으로는 AI 지원 진단 도구, 유전자 편집의 발전, 치료 전달에 대한 나노 기술의 적용, 혁신적인 생물학적 치료법, 웨어러블 모니터링 기술의 채택 등이 있습니다.

표적 치료에 대한 수요가 증가함에 따라 결절성 소양증 시장이 성장할 것으로 예상됩니다. 표적 치료는 질병 진행과 관련된 분자 경로를 구체적으로 표적으로 하는 의학적 치료법입니다. 표적 치료는 정밀성, 부작용 감소, 환자 치료 결과 개선으로 인기가 높아지고 있으며, 기존의 광범위한 치료법의 유망한 대안으로 떠오르고 있습니다. 결절성 소양증의 경우, IL-4, IL-13, IL-31과 같은 면역 경로와 관련된 명확한 미충족 의료 수요가 존재합니다. 표적 생물학적 제제는 이러한 염증 신호를 효과적으로 차단하여 더 성공적인 치료를 이끌 수 있습니다. 예를 들어, 2023년 10월, 영국 국민건강보험(NHS England)은 영국에서 1,100만 건의 호르몬 대체 요법(HRT)이 처방되어 2021-2022년에 비해 47% 증가했으며, 약 230만 명의 환자가 처방전을 받은 것으로 보고했습니다. 이는 표적 치료에 대한 수요가 증가하는 광범위한 동향을 보여 주며, 결절성 소양증 시장의 확장에 기여하고 있습니다.

결절성 소양증 시장의 주요 업체들은 시장 입지를 확대하고 치료 결과를 개선하기 위해 규제 당국의 승인을 강조하고 있습니다. 규제 당국의 승인은 정부 또는 규제 기관의 공식적인 승인을 의미하며, 특정 의약품 또는 치료법의 공개 사용 및 마케팅을 허용합니다. 예를 들어, 2022년 9월 미국에 본사를 두고 있는 바이오기술 기업 레제네론 파마슈티컬스(Regeneron Pharmaceuticals Inc.)는 듀피켄트(Dupixent, 듀필루맙)에 대해 FDA 승인을 획득했습니다. 이는 성인 노드라리우스성 소양증 치료를 위해 명시적으로 승인된 첫 번째이자 유일한 치료제입니다. 이 승인은 Phase 3 임상 시험인 PRIME과 PRIME2에서 듀피켄트가 위약 대비 소양증과 피부 병변을 유의미하게 감소시켰다는 결과를 바탕으로 이루어졌습니다. 이로써 듀픽센트는 미국에서 노드라리스성 소양증 치료를 위한 승인된 적응증을 가진 유일한 약물로 자리매김했으며, 약 7만 5,000명의 환자의 치료 수요를 충족시키게 되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 결절성 소양증 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 결절성 소양증 시장 : 성장률 분석
• 세계의 결절성 소양증 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 결절성 소양증 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 결절성 소양증 : 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 결절성 소양증 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 만성 결절성 소양증
• 급성 결절성 소양증
• 아급성 결절성 소양증
• 세계의 결절성 소양증 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 국소 치료
• 전신치료
• 광선 요법
• 면역억제제
• 세계의 결절성 소양증 시장 : 환자 인구 통계별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 성인
• 유아
• 고령자
• 세계의 결절성 소양증 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 재택치료
• 전문 클리닉
• 기타
• 세계의 결절성 소양증 시장 : 만성 결절성 소양증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 특발성 만성 결절성 소양증
• 피부질환의 원인
• 신경장애의 원인
• 전신성 질환 관련
• 심인성 소양증
• 세계의 결절성 소양증 시장 : 급성 결절성 소양증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 벌레 물린
• 알레르기 반응
• 약제성 소양증
• 감염의 유인
• 세계의 결절성 소양증 시장 : 아급성 결절성 소양증 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 만성 소양증의 치유기
• 염증 후 소양증
• 일과성 피부질환
• 환경 자극 물질에 대한 반응

제7장 지역별, 국가별 분석

• 세계의 결절성 소양증 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 결절성 소양증 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 결절성 소양증 시장 : 경쟁 구도
• 결절성 소양증 시장 : 기업 프로파일
  • Merck & Co Inc.
  • Sanofi SA
  • GlaxoSmithKline plc
  • Amgen Inc.
  • Regeneron Pharmaceuticals Inc.

제31장 기타 주요 기업 및 혁신 기업

• Astellas Pharma Inc.
• Sun Pharmaceutical Industries Limited
• Galderma SA
• Galderma Laboratories LP
• Incyte Corporation
• Kyowa Kirin Co Ltd.
• LEO Pharma A/S
• Maruho Co Ltd.
• Kiniksa Pharmaceuticals Ltd.
• Keymed Biosciences Co Ltd.
• Trevi Therapeutics Inc.
• Fierce Pharma
• Menlo Therapeutics Inc.
• VYNE Therapeutics Inc.
• Celldex Therapeutics Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

• 결절성 소양증 시장(2029년) : 새로운 기회를 제공하는 국가
• 결절성 소양증 시장(2029년) : 새로운 기회를 제공하는 부문
• 결절성 소양증 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

HBR

영문 목차

영문목차

Nodular prurigo, also referred to as prurigo nodularis, is a chronic dermatological condition characterized by extremely itchy, firm nodules that typically develop on areas such as the arms, legs, and torso. It is a persistent disorder of unknown origin involving immune, neurological, and inflammatory mechanisms, where continuous itching prompts repetitive scratching, leading to lesion aggravation, scarring, and often requiring long-term medical management by dermatologists.

The primary classifications of nodular prurigo include chronic nodular prurigo, acute nodular prurigo, and subacute nodular prurigo. Chronic nodular prurigo is a prolonged variant marked by the appearance of highly itchy, firm skin bumps. Treatments for the condition vary and may involve topical applications, systemic medications, phototherapy, and immunosuppressive agents. This condition affects various demographic groups, including adults, children, and the elderly, and treatment services are provided across different settings such as hospitals, homecare, specialty clinics, and others.

The nodular prurigo market research report is one of a series of new reports from The Business Research Company that provides nodular prurigo market statistics, including nodular prurigo industry global market size, regional shares, competitors with a nodular prurigo market share, nodular prurigo market segments, market trends and opportunities, and any further data you may need to thrive in the nodular prurigo industry. This nodular prurigo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nodular prurigo market size has grown strongly in recent years. It will grow from $1.17 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. Growth in the historical period was supported by an increase in dermatological consultations, greater awareness among skin specialists, unmet treatment needs, academic interest in the condition, and advancements in diagnostic capabilities.

The nodular prurigo market size is expected to see strong growth in the next few years. It will grow to $1.60 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. Contributing factors to this projected growth include the introduction of targeted therapies, enhanced R&D investment for rare skin conditions, more robust patient education and advocacy initiatives, broader insurance and reimbursement availability, and the development of companion diagnostics and biomarkers. Noteworthy trends anticipated during the forecast period include AI-assisted diagnostic tools, gene editing advancements, nanotechnology applications in treatment delivery, innovative biologic therapies, and the adoption of wearable monitoring technologies.

The rising demand for targeted therapies is anticipated to drive the growth of the nodular prurigo market. Targeted therapies are medical treatments designed to specifically interact with molecular pathways involved in disease progression. Their growing popularity stems from their precision, reduced side effects, and enhanced patient outcomes, making them favorable alternatives to traditional, broad-spectrum treatments. In the case of nodular prurigo, which presents a clear unmet need involving immune pathways such as IL-4, IL-13, and IL-31, targeted biologics can effectively block these inflammatory signals, leading to more successful treatment. For example, in October 2023, NHS England reported that 11 million hormone replacement therapy (HRT) items were prescribed in England-a 47% increase from 2021-22-with approximately 2.3 million patients receiving prescriptions, reflecting a 29% year-on-year growth. This illustrates the broader trend of increased demand for targeted therapies, which is contributing to the expansion of the nodular prurigo market.

Major players in the nodular prurigo market are emphasizing regulatory approvals to broaden their market presence and enhance treatment outcomes. Regulatory approvals involve official authorization from government or regulatory agencies, allowing the public use and marketing of specific drugs or therapies. For example, in September 2022, Regeneron Pharmaceuticals Inc., a biotechnology firm based in the U.S., obtained FDA approval for Dupixent (dupilumab), making it the first and only treatment explicitly approved for prurigo nodularis in adults. This approval followed successful Phase 3 trials-PRIME and PRIME2-which showed Dupixent significantly reduced itch and skin lesions compared to placebo. As a result, Dupixent emerged as the only medication in the U.S. with an approved indication for treating prurigo nodularis, addressing the needs of approximately 75,000 affected adults.

In April 2024, Incyte Corporation, a U.S.-based pharmaceutical company, formed a partnership with China Medical System Holdings Limited to advance the development and commercialization of Povorcitinib across Asia. The collaboration aims to support the treatment of various autoimmune and inflammatory dermatologic conditions, including non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria. China Medical System Holdings Limited, based in Hong Kong, is actively involved in treatments related to nodular prurigo.

Major players in the nodular prurigo market are Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Galderma S.A., Galderma Laboratories L.P., Incyte Corporation, Kyowa Kirin Co Ltd., LEO Pharma A/S, Maruho Co Ltd., Kiniksa Pharmaceuticals Ltd., Keymed Biosciences Co Ltd., Trevi Therapeutics Inc., Fierce Pharma, Menlo Therapeutics Inc., VYNE Therapeutics Inc., and Celldex Therapeutics Inc.

North America was the largest region in the nodular prurigo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nodular prurigo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nodular prurigo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nodular prurigo market consists of revenues earned by entities by providing services such as diagnosis and clinical evaluation, prescription of topical treatments, phototherapy, biologic therapies, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The nodular prurigo market also includes sales of products including oral antidepressants, JAK inhibitors, and topical calcineurin inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nodular Prurigo Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nodular prurigo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nodular prurigo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nodular prurigo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Chronic Nodular Prurigo; Acute Nodular Prurigo; Subacute Nodular Prurigo
• 2) By Treatment Type: Topical Treatments; Systemic Treatments; Phototherapy; Immunosuppressants
• 3) By Patient Demographics: Adults; Children; Elderly
• 4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Chronic Nodular Prurigo: Idiopathic Chronic Nodular Prurigo; Secondary To Dermatologic Conditions; Neuropathic Causes; Systemic Disease-Associated; Psychogenic Prurigo
• 2) By Acute Nodular Prurigo: Insect Bite-Induced; Allergic Reactions; Drug-Induced Prurigo; Infectious Triggers
• 3) By Subacute Nodular Prurigo: Healing Phase Of Chronic Prurigo; Post-Inflammatory Prurigo; Transient Dermatoses; Reaction To Environmental Irritants
• Companies Mentioned: Merck & Co Inc.; Sanofi S.A.; GlaxoSmithKline plc; Amgen Inc.; Regeneron Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nodular Prurigo Market Characteristics

3. Nodular Prurigo Market Trends And Strategies

4. Nodular Prurigo Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Nodular Prurigo Growth Analysis And Strategic Analysis Framework

• 5.1. Global Nodular Prurigo PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Nodular Prurigo Market Growth Rate Analysis
• 5.4. Global Nodular Prurigo Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Nodular Prurigo Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Nodular Prurigo Total Addressable Market (TAM)

6. Nodular Prurigo Market Segmentation

• 6.1. Global Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Nodular Prurigo
• Acute Nodular Prurigo
• Subacute Nodular Prurigo
• 6.2. Global Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Treatments
• Systemic Treatments
• Phototherapy
• Immunosuppressants
• 6.3. Global Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adults
• Children
• Elderly
• 6.4. Global Nodular Prurigo Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.5. Global Nodular Prurigo Market, Sub-Segmentation Of Chronic Nodular Prurigo, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Idiopathic Chronic Nodular Prurigo
• Secondary To Dermatologic Conditions
• Neuropathic Causes
• Systemic Disease-Associated
• Psychogenic Prurigo
• 6.6. Global Nodular Prurigo Market, Sub-Segmentation Of Acute Nodular Prurigo, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insect Bite-Induced
• Allergic Reactions
• Drug-Induced Prurigo
• Infectious Triggers
• 6.7. Global Nodular Prurigo Market, Sub-Segmentation Of Subacute Nodular Prurigo, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Healing Phase Of Chronic Prurigo
• Post-Inflammatory Prurigo
• Transient Dermatoses
• Reaction To Environmental Irritants

7. Nodular Prurigo Market Regional And Country Analysis

• 7.1. Global Nodular Prurigo Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Nodular Prurigo Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nodular Prurigo Market

• 8.1. Asia-Pacific Nodular Prurigo Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nodular Prurigo Market

• 9.1. China Nodular Prurigo Market Overview
• 9.2. China Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nodular Prurigo Market

• 10.1. India Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nodular Prurigo Market

• 11.1. Japan Nodular Prurigo Market Overview
• 11.2. Japan Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nodular Prurigo Market

• 12.1. Australia Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nodular Prurigo Market

• 13.1. Indonesia Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nodular Prurigo Market

• 14.1. South Korea Nodular Prurigo Market Overview
• 14.2. South Korea Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nodular Prurigo Market

• 15.1. Western Europe Nodular Prurigo Market Overview
• 15.2. Western Europe Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nodular Prurigo Market

• 16.1. UK Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nodular Prurigo Market

• 17.1. Germany Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nodular Prurigo Market

• 18.1. France Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nodular Prurigo Market

• 19.1. Italy Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nodular Prurigo Market

• 20.1. Spain Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nodular Prurigo Market

• 21.1. Eastern Europe Nodular Prurigo Market Overview
• 21.2. Eastern Europe Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nodular Prurigo Market

• 22.1. Russia Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nodular Prurigo Market

• 23.1. North America Nodular Prurigo Market Overview
• 23.2. North America Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nodular Prurigo Market

• 24.1. USA Nodular Prurigo Market Overview
• 24.2. USA Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nodular Prurigo Market

• 25.1. Canada Nodular Prurigo Market Overview
• 25.2. Canada Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nodular Prurigo Market

• 26.1. South America Nodular Prurigo Market Overview
• 26.2. South America Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nodular Prurigo Market

• 27.1. Brazil Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nodular Prurigo Market

• 28.1. Middle East Nodular Prurigo Market Overview
• 28.2. Middle East Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nodular Prurigo Market

• 29.1. Africa Nodular Prurigo Market Overview
• 29.2. Africa Nodular Prurigo Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Nodular Prurigo Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Nodular Prurigo Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nodular Prurigo Market Competitive Landscape And Company Profiles

• 30.1. Nodular Prurigo Market Competitive Landscape
• 30.2. Nodular Prurigo Market Company Profiles
  • 30.2.1. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Nodular Prurigo Market Other Major And Innovative Companies

• 31.1. Astellas Pharma Inc.
• 31.2. Sun Pharmaceutical Industries Limited
• 31.3. Galderma S.A.
• 31.4. Galderma Laboratories L.P.
• 31.5. Incyte Corporation
• 31.6. Kyowa Kirin Co Ltd.
• 31.7. LEO Pharma A/S
• 31.8. Maruho Co Ltd.
• 31.9. Kiniksa Pharmaceuticals Ltd.
• 31.10. Keymed Biosciences Co Ltd.
• 31.11. Trevi Therapeutics Inc.
• 31.12. Fierce Pharma
• 31.13. Menlo Therapeutics Inc.
• 31.14. VYNE Therapeutics Inc.
• 31.15. Celldex Therapeutics Inc.

32. Global Nodular Prurigo Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nodular Prurigo Market

34. Recent Developments In The Nodular Prurigo Market

35. Nodular Prurigo Market High Potential Countries, Segments and Strategies

• 35.1 Nodular Prurigo Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Nodular Prurigo Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Nodular Prurigo Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료